» Articles » PMID: 27498787

MicroRNA-140 Represses Glioma Growth and Metastasis by Directly Targeting ADAM9

Overview
Journal Oncol Rep
Specialty Oncology
Date 2016 Aug 9
PMID 27498787
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma is the most frequent primary malignant tumor of the human brain. Recently, great progress has been made in the combined therapy of glioma. However, the clinical effects of these treatments and prognosis for patients with glioma remains poor. MicroRNAs (miRNAs) have been demonstrated to play important roles in the initiation and progression of various types of human cancers, also including glioma. The present study investigated the expression patterns of microRNA‑140 (miR-140) in glioma, and the roles of miR-140 in glioma cell proliferation, migration and invasion. The results showed that miR-140 was significantly downreuglated in glioma tissues and cell lines, and low expression levels of miR-140 were correlated with World Health Organization (WHO) grade and Karnofsky performance score (KPS) of glioma patients. Restoration of miR-140 obviously suppressed glioma cell proliferation, migration and invasion. In addition, a disintegrin and metalloproteinase 9 (ADAM9) was identified as a novel direct target gene of miR-140 in glioma. Furthermore, knockdown of ADAM9 simulated the tumor suppressor functions of miR-140, while overexpression of ADAM9 abrogated these suppressive effects induced by miR-140 in glioma cells. In conclusion, the present study demonstrated the expression and clinical roles of miR-140 in glioma and suggested that miR-140 inhibited proliferation, migration and invasion of glioma cells, partially at least via suppressing ADAM9 expression. Therefore, miR-140 may be a novel candidate target for the development of therapeutic strategies for patients with glioma.

Citing Articles

MicroRNAs and proteolytic cleavage of receptors in cancers: A comprehensive review of regulatory interactions and therapeutic implications.

Hosseinpour-Soleimani F, Salmasi Z, Ghasemi Y, Tajbakhsh A, Savardashtaki A Heliyon. 2024; 10(7):e28167.

PMID: 38560206 PMC: 10979173. DOI: 10.1016/j.heliyon.2024.e28167.


Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets.

Kciuk M, Yahya E, Mohamed M, Abdulsamad M, Allaq A, Gielecinska A Cancers (Basel). 2023; 15(13).

PMID: 37444408 PMC: 10340789. DOI: 10.3390/cancers15133298.


Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets.

Hua T, Zeng Z, Chen J, Xue Y, Li Y, Sang Q Cancers (Basel). 2022; 14(15).

PMID: 35954348 PMC: 9367328. DOI: 10.3390/cancers14153685.


Non-coding RNAs and glioblastoma: Insight into their roles in metastasis.

Mousavi S, Derakhshan M, Baharloii F, Dashti F, Mirazimi S, Mahjoubin-Tehran M Mol Ther Oncolytics. 2022; 24:262-287.

PMID: 35071748 PMC: 8762369. DOI: 10.1016/j.omto.2021.12.015.


An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Grixti J, Ayers D, Day P Noncoding RNA. 2021; 7(2).

PMID: 33923485 PMC: 8167612. DOI: 10.3390/ncrna7020027.